Market Overview

Morgan Stanley Sees End-Market Pressure On Hill-Rom

Related HRC
Walgreens-Greater Than AIDS Unite to Serve Against HIV/AIDS
Hologic Receives Extended FDA Clearance for SculpSure in US

In a report published Tuesday, Morgan Stanley analyst David R. Lewis reiterated an Underweight rating and $36.00 price target on Hill-Rom Holdings (NYSE: HRC).

In the report, Morgan Stanley noted, “We are supportive of the deal, but remain underweight on end-market pressure. More diversity is needed, which will continually put valuation at risk, but the returns and channel leverage from the TRUMPF deal make us more positive than we were on Aspen.”

Hill-Rom closed on Monday at $40.09.

Latest Ratings for HRC

Jun 2017NeedhamInitiates Coverage OnBuy
Jun 2017Cantor FitzgeraldInitiates Coverage OnNeutral
Feb 2017BarclaysInitiates Coverage OnOverweight

View More Analyst Ratings for HRC
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings


Related Articles (HRC)

View Comments and Join the Discussion!